MaxCyte Licenses Multi-Platform Cell Engineering Technology to Genentech for Cell Therapy Development
核心洞察
MaxCyte (搜索) has entered a multi-platform technology license agreement with Genentech, a Roche Group member, to support cell therapy programs from discovery through cGMP manufacturing.
The non-exclusive license provides Genentech access to MaxCyte (搜索)'s ExPERT GTx platform and flow electroporation technology for ex vivo cell engineering without viral vectors.
The agreement spans multiple internal Genentech programs rather than a single therapeutic candidate, though specific programs and financial terms were not disclosed.
MaxCyte (搜索), Inc. (Nasdaq: MXCT), a Rockville, Maryland-based cell-engineering company, announced on July 21, 2026 that it has entered into a multi-platform technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs across research, clinical development, and manufacturing workflows.
The agreement provides Genentech with non-exclusive access to MaxCyte (搜索)'s ExPERT GTx platform and additional undisclosed platform technologies for ex vivo cell engineering. The license is structured to support multiple internal Genentech programs rather than a single therapeutic candidate, spanning from early discovery through cGMP manufacturing.
"Cell therapy development increasingly requires technology partners that can support programs as they advance from research through development and manufacturing," said Maher Masoud, President and CEO of MaxCyte (搜索). "This partnership allows MaxCyte to provide broader support to Genentech across the cell therapy lifecycle by bringing together complementary capabilities in cell engineering and gene editing. Through integrated access to these platforms, we are helping partners move forward with greater speed, confidence, and continuity."
Flow Electroporation Technology
MaxCyte (搜索)'s flow electroporation systems use electrical pulses to transiently permeabilize cell membranes, enabling delivery of nucleic acids and other cargo without the use of viral vectors. The technology is already employed in commercial manufacturing, most notably for Legend Biotech's approved CAR-T therapy Carvykti.
The capabilities across MaxCyte (搜索)'s platform technologies are designed to streamline the advancement of cell therapy programs by providing integrated access to support cell engineering from early discovery through cGMP manufacturing. The partnership underscores MaxCyte's expertise in enabling next-generation cell therapies by bringing together complementary technologies that support both cell engineering and analytical workflows across the development lifecycle.
Roche's Expanding Cell Therapy Footprint
The deal expands Genentech's cell therapy manufacturing capabilities as Roche continues to build its presence in the field. In late 2024, Genentech acquired Poseida Therapeutics, adding a portfolio of non-viral cell therapy candidates and transposon technology to its pipeline. Roche is also developing the retinal pigment epithelium cell therapy OpRegen (RG6501) with Lineage Cell Therapeutics for geographic atrophy (搜索).
MaxCyte (搜索)'s Growing Commercial Partnerships
For MaxCyte (搜索), the Genentech agreement adds another major pharmaceutical customer to its platform licensing business. The company has signed approximately 30 strategic platform license agreements, which typically combine upfront licensing fees with development milestones, royalties, and instrument sales. MaxCyte has recently expanded its commercial reach through an exclusive distribution agreement with PHC Holdings in Japan and a co-development collaboration with VectorBuilder focused on non-viral gene delivery for cell therapy manufacturing.
Neither company disclosed the agreement's duration, financial terms, or the specific Genentech programs that will use the licensed technologies.